EMA Authorised: Abiraterone Accord (abiraterone acetate) — Accord Healthcare S.L.U.

View source ↗

Summary

The European Medicines Agency authorised Abiraterone Accord (abiraterone acetate) for use in prostate cancer, with Accord Healthcare S.L.U. as the marketing aut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone Accord (abiraterone acetate)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Accord Healthcare S.L.U.. Decision date: 19/12/2025